comparemela.com
Home
Live Updates
Seelos Therapeutics Announces Top Line Results from SLS-002
Seelos Therapeutics Announces Top Line Results from SLS-002
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
SLS-002 demonstrated early and persistent clinically meaningful reductions in symptoms of depression and acute suicidality Robust Response and Remission Rates were observed using the...
Related Keywords
New York ,
United States ,
Davidv Sheehan ,
Tim Whitaker ,
Anthony Marciano ,
Lifesci Advisors ,
Seelos Therapeutics Inc ,
Javelin Pharmaceuticals Inc Hospira ,
Agency For Healthcare Research ,
Exchange Commission ,
Nasdaq ,
Prnewswire Seelos Therapeutics Inc ,
Remission Rates ,
Depression Rating Scale ,
Acute Suicidal Ideation ,
Major Depressive Disorder ,
Chief Medical Officer ,
Key Efficacy ,
Administered Dissociative States Scale ,
Sedation Scale ,
Post Traumatic Stress ,
Javelin Pharmaceuticals ,
Healthcare Research ,
Private Securities Litigation Reform Act ,
Annual Report ,
Quarterly Reports ,
Sci Advisors ,
Markets ,